PLoS Genetics (Sep 2018)

Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis.

  • William P D Hendricks,
  • Victoria Zismann,
  • Karthigayini Sivaprakasam,
  • Christophe Legendre,
  • Kelsey Poorman,
  • Waibhav Tembe,
  • Nieves Perdigones,
  • Jeffrey Kiefer,
  • Winnie Liang,
  • Valerie DeLuca,
  • Mitchell Stark,
  • Alison Ruhe,
  • Roe Froman,
  • Nicholas S Duesbery,
  • Nicholas S Duesbery,
  • Megan Washington,
  • Jessica Aldrich,
  • Mark W Neff,
  • Matthew J Huentelman,
  • Nicholas Hayward,
  • Kevin Brown,
  • Douglas Thamm,
  • Gerald Post,
  • Chand Khanna,
  • Barbara Davis,
  • Matthew Breen,
  • Alexander Sekulic,
  • Jeffrey M Trent

DOI
https://doi.org/10.1371/journal.pgen.1007589
Journal volume & issue
Vol. 14, no. 9
p. e1007589

Abstract

Read online

Canine malignant melanoma, a significant cause of mortality in domestic dogs, is a powerful comparative model for human melanoma, but little is known about its genetic etiology. We mapped the genomic landscape of canine melanoma through multi-platform analysis of 37 tumors (31 mucosal, 3 acral, 2 cutaneous, and 1 uveal) and 17 matching constitutional samples including long- and short-insert whole genome sequencing, RNA sequencing, array comparative genomic hybridization, single nucleotide polymorphism array, and targeted Sanger sequencing analyses. We identified novel predominantly truncating mutations in the putative tumor suppressor gene PTPRJ in 19% of cases. No BRAF mutations were detected, but activating RAS mutations (24% of cases) occurred in conserved hotspots in all cutaneous and acral and 13% of mucosal subtypes. MDM2 amplifications (24%) and TP53 mutations (19%) were mutually exclusive. Additional low-frequency recurrent alterations were observed amidst low point mutation rates, an absence of ultraviolet light mutational signatures, and an abundance of copy number and structural alterations. Mutations that modulate cell proliferation and cell cycle control were common and highlight therapeutic axes such as MEK and MDM2 inhibition. This mutational landscape resembles that seen in BRAF wild-type and sun-shielded human melanoma subtypes. Overall, these data inform biological comparisons between canine and human melanoma while suggesting actionable targets in both species.